Relative Quantification of ERBB2 mRNA in Invasive Duct Carcinoma of the Breast: Correlation with ERBB-2 Protein Expression and ERBB2 Gene Copy Number

https://doi.org/10.1078/0344-0338-00445Get rights and content

Summary

The option to treat patients suffering from ERBB-2 protein-positive invasive duct carcinomas of the breast (IDC) with Herceptin requires a precise determination of the ERBB2 status. The aim of the study was to evaluate the ERBB2 mRNA level, placing emphasis on cases with discordant findings between ERBB-2 protein expression (IHC) and a copy number of the ERBB2 gene (FISH). Thirty-nine IDCs (21 cases IHC and FISH concordant, 15 cases moderately discordant, 3 cases markedly discordant) were investigated. ERBB2 mRNA expression was determined using quantitative real-time RT-PCR (Q-RT-PCR). IDCs with negative ERBB-2 protein and without ERBB2 gene amplification had a low ERBB2 mRNA level. Cases with 3+ overexpression of the protein and with strong gene amplification (>10 copies/tumor cell) had a significantly increased expression of ERBB2 mRNA. In 13 of 15 IDCs with moderate discrepancies (up to 10 copies of the gene per one tumor cell/negative ERBB-2 protein; without amplification/2+ protein) mRNA was low, comparable to that in cases with negative ERBB-2 protein and without ERBB2 gene amplification. In three cases with markedly discordant findings (the gene amplified/protein negative – one case; protein 3+/no amplification – 2 cases), Q-RT-PCR results were within a “normal” limit. Ineffective gene amplification and protein accumulation are suggested explanations. Q-RT-PCR revealed two cases with highly expressed ERBB2 mRNA and discordant FISH and/or IHC findings. Increased effectiveness of transcription (protein 2+/high mRNA/without the gene amplification), and combined dysregulation (protein negative/high mRNA/no amplification) are possible causes of these findings. Q-RT-PCR appears useful in clarifying borderline or discrepant IHC and FISH findings.

References (34)

  • J.M. Bartlett et al.

    Evaluating HER2 amplification and overexpression in breast cancer

    J Pathol

    (2001)
  • I. Bieche et al.

    Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications

    Clin Chem

    (1999)
  • L. Coussens et al.

    Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

    Science

    (1985)
  • M.S. de Lange et al.

    A method to monitor mRNA levels in human breast tumor cells obtained by fine-needle aspiration

    Diagn Mol Pathol

    (1997)
  • C.W. Elston et al.

    Assessment of histological grade

  • M.P. Hoang et al.

    HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma

    Am J Clin Pathol

    (2000)
  • M.C. Hung et al.

    Basic science of HER-2/neu: a review

    Semin Oncol

    (1999)
  • Cited by (18)

    • Evaluation of HER2 gene status in breast cancer samples with indeterminate fluorescence in situ hybridization by quantitative real-time PCR

      2015, Journal of Molecular Diagnostics
      Citation Excerpt :

      To maintain high specificity, sensitivity, and performance (amplification success) of the qPCR method, we finally evaluated samples as HER2 amplified if HER2-to-reference gene copy number ratios were ≥2.2 for at least two of the reference genes. Surprisingly, although qPCR techniques are often used to detect HER2 mRNA,25–27 DNA-based PCR is not widely used to determine HER2 gene status, except by the LightCycler HER2/neu DNA Quantification kit (Roche, Mannheim, Germany).24,28–31 However, this kit only uses a single reference gene (not specified) located on chromosome 17, for which copy numbers frequently change in human cancers,32 and use of a single reference gene can clearly impair the reliability of HER2 analysis and amplification performance.

    • Assessment of HER-2 gene overexpression in Isfahan province breast cancer patients using Real Time RT-PCR and immunohistochemistry

      2013, Gene
      Citation Excerpt :

      The routine test that is commonly used for detecting HER-2 protein overexpression is IHC, while fluorescence in-situ hybridization (FISH) is a common method for evaluating HER-2 gene amplification. More recently, Real Time Reverse Transcriptase-Polymerase Chain Reaction (Real Time RT-PCR) has been used as a complementary method for determining the level of HER-2 mRNA, but the results remain challenging and conflicting (Bossard et al., 2005; Ginestier et al., 2004; Mrhalová et al., 2003; Vinatzer et al., 2005). In the present study, we analyzed expression levels of HER-2 in human breast carcinomas and also we compared the expression levels of HER-2 mRNA with IHC scores.

    • Comparative evaluation of non-informative HER-2 immunoreactions (2<sup>+</sup>) in breast carcinomas with FISH, CISH and QRT-PCR

      2007, Breast
      Citation Excerpt :

      Notably, there were cases with “low-level amplification” that showed mRNA values overlapping with those of polysomic cases and it was difficult to define cut-off values. This difficulty apparently was experienced by other investigators.19,20,22,25,28 In addition, we had to overcome technical obstacles while attempting to work with paraffin-embedded samples.

    View all citing articles on Scopus
    View full text